EnteroMedics (ETRM) Stock: Gains As Investors Await Presentations

EnteroMedics Inc (NASDAQ: ETRM) is having a strong start to the trading session in the pre-market hours this morning as investors await a presentation that was just announced yesterday. Of course our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:09), ETRM is trading at $2.29 per share after a gain of $0.05 per share or 2.23% thus far today.

ETRM Gains Ahead Of Coming Presentations

As mentioned above, EnteroMedics is having a strong start to the trading session in the pre-market hours this morning. Yesterday, the company announced that it and its products will be the subjects of two oral presentations and one poster presentation at ObesityWeek 2017. The presentations will take place in Washington D.C. from October 29th through November 2nd. The presentations will feature vBloc® Real-World patient data, ReShape® integrated dual balloon system patient data, and Gastric VestTM System initial clinical results. For more information surrounding ObesityWeek 2017 and the involvement of ETRM in the conference, click here.

What Investors Want To See

While vBloc is an important piece of the ETRM offering, it’s not going to be the center of attention among most investors at this presentation. However, Gastric Vest and ReShape will be two big topics of discussion. As most following EnteroMedics already know, the company is working to bring Gastric Vest to market. Considering this, the clinical data that the company intends on offering at the presentation will be a key bit of information with regard to the efforts to bring the system to market. So, investors will likely be keeping a close eye on what data and other news is released surrounding the system.

On top of that, very recently, ETRM announced the acquisition of the ReShape Dual Weight Loss Balloon. This product is an FDA-approved, minimally invasive intragastric balloon designed to treat obesity patients with a BMI of between 30 and 40 with one or more related comorbid conditions. Considering that this is a recent acquisition, investors are likely excited to see the first bit of real-world data that will be released by ETRM themselves. Of course, positive data here would suggest that commercialization of the treatment will move at a decent pace, leading to strong gains in the value of the stock. In a statement with regard to the acquisition of ReShape, Dan Gladney, President, CEO and Chairman of the Board at EnteroMedics, recently had the following to offer:

We are pleased to announce this significant transaction, which adds a new minimally invasive, revenue-generating technology to the EnteroMedics portfolio… The acquisition of the ReShape Dual Weight Loss Balloon, which complements our existing products with a non-surgical weight loss solution expands our addressable market and gives us yet another touch point along the continuum of care in obesity.

EnteroMedics and ReShape Medical are two innovative companies that share a strong strategic focus on providing proprietary, patient-friendly technologies to address the global obesity epidemic… We look forward to combining the complementary expertise and capabilities of both companies for the benefit of our customers, patients, employees and stockholders.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ETRM. In particular, we’re interested in following the story surrounding the presentation and looking forward to both the clinical data surrounding Gastric Vest and the real-world data surrounding ReShape. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Leave a Comment